| This meeting was only intended for healthcare professionals from the UK and Ireland. This meeting was organised and funded by Teva and included mention of Teva product(s). Prescribing information was available at the meeting and is available in the links below. |
| Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0)207 540 7117, or email uk.safety@tevauk.com. |
Behavioural change for migraine prevention
From Head Start's Annual Meeting, June 2024
Professor Ivo Vlaev discusses the application of behavioural science in migraine prevention
Professor Ivo Vlaev discusses the application of behavioural science in migraine prevention through the MINDSPACE framework, an acronym representing nine principles designed to influence behaviour in automatic ways.01
He outlines Nudge theory02 and provides examples for each principle, demonstrating how behaviour can be shaped. Professor Vlaev also explores how these concepts could be integrated into healthcare services to improve care for migraine patients and enhance service design.
Abbreviations
CGRP, calcitonin gene-related peptide; FASPS2, familial advanced sleep phase syndrome-2; HRT, hormone replacement therapy; ICS, integrated care systems; NICE, National Institute for Health and Care Excellence.
Discover more about Head Start's Annual MeetingPrescribing Information
References
-
Back to contents.
Dolan, P., Hallsworth, M., Halpern, D., King, D., & Vlaev, I. (2010). MINDSPACE: influencing behaviour for public policy.
-
Back to contents.
Thaler, R. & Sunstein, C. (2008) Nudge: improving decisions about health, wealth, and happiness. New Haven: Yale University Press, pp 6.
This meeting was open to HCPs from the UK and Ireland with an interest in headache and migraine. This meeting was organised and funded by Teva.
Registered in England No. 302461. Registered office: Teva UK Limited, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX
+44 (0) 1977 628500 | www.tevauk.com | Copyright © 2024 Teva UK Limited
Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0) 207 540 7117, or email uk.safety@tevauk.com.
Privacy Policy | Pharmacovigilance Privacy Policy | Terms and Conditions | Accessibility | Reporting Adverse Events